source
- Obesity drug market surges as Lilly, Novo Nordisk lead and rivals chase $200B opportunityEli Lilly and Novo Nordisk continue to dominate the early market for obesity treatments, expanding their prescription bases with new oral products. Meanwhile, a range of larger and smaller compani…
- AstraZeneca and Amgen’s Tezspire shows positive results in Phase 3 eosinophilic esophagitis trialAstraZeneca and Amgen continue to co‑develop and co‑commercialize Tezspire, an anti‑inflammatory therapy already approved for asthma and chronic rhinosinusitis. The partners are preparing another F…